The latest information about BioMark Diagnostics to keep you up to date.
BioMark Diagnostics is leading the world in early-stage cancer detection with an oncology focus designed to improve patient outcomes.
BIOMARK ANNOUNCES UPDATE FROM ONGOING CLINICAL TRIAL USING ITS LUNG CANCER LIQUID BIOSPY TEST AS
BIOMARK PROVIDES BUSINESS UPDATE AND SECOND QUARTER Financial RESULTS Vancouver, British Columbia – (November 28,
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and
THE US PATENT OFFICE GRANTS BIOMARK ADDITIONAL PATENT FOR ITS LIQUID BIOPSY TECHNOLOGY Vancouver, British
BioMark TO PRESENT VALIDATION DATA OF ITS Multianalyte Metabolite Panel for Lung Cancer Screening at
BIOMARK SELECTED BY THE MEDICAL ALLEY AND INVESTISSEMENT QUEBEC TO JOIN THE US GO-TO-MARKET ACCELERATOR
BIOMARK PROVIDES FIRST-QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL UPDATE Vancouver, British Columbia – (August 30,
BIOMARK PROVIDES FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2022, AND RECENT CORPORATE HIGHLIGHTS
Form 7 – Monthly CSE Progress Report June 2022 Name of Listed Issuer: Trading Symbol:
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2
Rashid A. Bux (CEO)
[email protected]